NCT04681079 is a clinical trial of albuterol sulfate (MDI) in COVID-19, sponsored by Theravance Biopharma.

Who is sponsoring NCT04681079?

NCT04681079 is sponsored by Theravance Biopharma.

What drugs are being tested in NCT04681079?

Interventions in NCT04681079: albuterol sulfate (MDI), albuterol sulfate (nebulizer).

Is NCT04681079 still recruiting?

NCT04681079 is currently completed. Last updated 28 January 2022.

Last reviewed 2022-01-28 · How we verify

NCT04681079

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

Completed Last updated 28 January 2022

What this trial tests

trial testing albuterol sulfate (MDI) in COVID-19 in 14 participants. Completed in 18 January 2022.

Timeline

4 May 2021

Primary endpoint
22 November 2021

18 January 2022

Quick facts

Lead sponsor	Theravance Biopharma
Status	Completed
Study type	OBSERVATIONAL
Enrollment	14
Start date	4 May 2021
Primary completion	22 November 2021
Estimated completion	18 January 2022
Sites	1 location across United States

Drugs / interventions tested

albuterol sulfate (MDI) — full drug profile →
albuterol sulfate (nebulizer) — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Theravance Biopharma — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, 2-period crossover, single-center, open-label study for viral sample collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and surface samplers will be used to assess viral loads in rooms of subjects with COVID-19.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019.
Pires C. · · 2021 · cited 14× · PMID 34575703 · DOI 10.3390/jpm11090926
Impact of nebulization versus metered-dose inhaler utilization on viral particle dispersion in patients with COVID-19.
Clemency BM, Clay C, Varughese R, Kennedy C, et al · · 2025 · cited 2× · PMID 39544634 · DOI 10.1177/17571774241266420

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Theravance Biopharma trials

Trials by the same sponsor.

NCT05165485 — Phase 4 COPD and Suboptimal Inspiratory Flow Rate · Phase 4 · completed
NCT05091723 — TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation · Phase 1 · completed
NCT04688632 — Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects · Phase 1 · completed
NCT04587713 — Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects · Phase 1 · completed
NCT04589260 — TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04681079 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Theravance Biopharma
Last refreshed: 28 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04681079.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing